BR112017000953A2 - formulação de comprimido de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida - Google Patents

formulação de comprimido de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida

Info

Publication number
BR112017000953A2
BR112017000953A2 BR112017000953A BR112017000953A BR112017000953A2 BR 112017000953 A2 BR112017000953 A2 BR 112017000953A2 BR 112017000953 A BR112017000953 A BR 112017000953A BR 112017000953 A BR112017000953 A BR 112017000953A BR 112017000953 A2 BR112017000953 A2 BR 112017000953A2
Authority
BR
Brazil
Prior art keywords
methyl
triazin
quinolin
imidazo
benzamide
Prior art date
Application number
BR112017000953A
Other languages
English (en)
Other versions
BR112017000953B1 (pt
Inventor
TAUCHMANN Christin
Gonçalves Elisabete
Yen Shau-Fong
Vippagunta Sudha
Zong Zhixin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017000953(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017000953A2 publication Critical patent/BR112017000953A2/pt
Publication of BR112017000953B1 publication Critical patent/BR112017000953B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se aos comprimidos compreendendo 2-flúor-n-metil-4-[7-(quinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida, os processo para a produção do mesmo, e usos no tratamento de certos cânceres.
BR112017000953-6A 2014-07-25 2015-07-22 Comprimido compreendendo 2-flúor-n-metil-4-[7-(quinolin6-il-metil) imidazo[1,2-b][1,2,4]triazin-2-il]benzamida BR112017000953B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
US62/028,865 2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Publications (2)

Publication Number Publication Date
BR112017000953A2 true BR112017000953A2 (pt) 2017-11-14
BR112017000953B1 BR112017000953B1 (pt) 2023-05-30

Family

ID=

Also Published As

Publication number Publication date
WO2016012963A1 (en) 2016-01-28
HUE053346T2 (hu) 2021-06-28
JP6770946B2 (ja) 2020-10-21
EP3172209A1 (en) 2017-05-31
MX2021000595A (es) 2021-04-13
AU2018207947A1 (en) 2018-08-09
EA039220B1 (ru) 2021-12-20
PT3172209T (pt) 2021-02-11
GT201700007A (es) 2018-12-18
PL3172209T3 (pl) 2021-06-14
SG11201700147SA (en) 2017-02-27
CL2017000180A1 (es) 2017-09-15
JP2017521469A (ja) 2017-08-03
TW201613595A (en) 2016-04-16
AU2020200912B2 (en) 2021-01-28
IL250166B (en) 2021-01-31
AU2015293539A1 (en) 2017-02-02
US10596178B2 (en) 2020-03-24
US20220249498A1 (en) 2022-08-11
FR22C1058I1 (fr) 2023-01-06
US20170231997A1 (en) 2017-08-17
EA201790259A1 (ru) 2017-06-30
FR22C1058I2 (fr) 2023-11-17
AU2020200912A1 (en) 2020-02-27
CN106714784A (zh) 2017-05-24
US20190015418A1 (en) 2019-01-17
PH12017500121A1 (en) 2017-05-29
KR102581121B1 (ko) 2023-09-21
JP2022046659A (ja) 2022-03-23
AU2021202500A1 (en) 2021-05-20
MY187276A (en) 2021-09-17
ES2857523T3 (es) 2021-09-29
EP3172209B1 (en) 2020-12-02
CN115364061A (zh) 2022-11-22
CO2017000586A2 (es) 2017-06-20
TWI724993B (zh) 2021-04-21
EP3848376A1 (en) 2021-07-14
ECSP17011672A (es) 2018-03-31
HUS2200054I1 (hu) 2023-01-28
TW202200148A (zh) 2022-01-01
PE20170523A1 (es) 2017-05-17
US10085993B2 (en) 2018-10-02
NZ728089A (en) 2024-01-26
MX2017001177A (es) 2017-05-01
KR20230136693A (ko) 2023-09-26
DK3172209T3 (da) 2021-02-22
JO3618B1 (ar) 2020-08-27
SI3172209T1 (sl) 2021-03-31
JP7002587B2 (ja) 2022-01-20
AR101286A1 (es) 2016-12-07
CA2954840A1 (en) 2016-01-28
US20210113569A1 (en) 2021-04-22
KR20170039211A (ko) 2017-04-10
SG10201900648SA (en) 2019-02-27
JP2020114852A (ja) 2020-07-30
IL250166A0 (en) 2017-03-30
EA202191301A1 (ru) 2021-11-30

Similar Documents

Publication Publication Date Title
PE20180521A1 (es) Inhibidores de tirosina-cinasas
CA158246S (en) Baby monitor baby unit
CA158245S (en) Baby monitor parent unit
CO2017000586A2 (es) Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
CA158251S (en) Cap for bottle
BR112016025396A2 (pt) derivados de heterociclil-butanamida
CA161877S (en) Capsule containing washing products
CA161878S (en) Capsule containing washing products
BR112015032357A8 (pt) processos para produção de cacau natural marrom escuro e vermelho escuro
NI201900023A (es) 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
CA161879S (en) Capsule containing washing products
CA161876S (en) Capsule containing washing products
CA158249S (en) Bottle
UY35715A (es) Proceso para preparar dronedarona y sales de la misma
CA166429S (en) Baby monitor
ECSP18000097A (es) Inhibidores de tirosina-cinasas
CA166428S (en) Baby monitor
TH159620B (th) กำไลข้อมือ
TH159619B (th) กำไลข้อมือ
CA160494S (en) Diamond
IN2013MU03855A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2015, OBSERVADAS AS CONDICOES LEGAIS